Nano Cap New Millennium Growth Fund L P Invests $399,000 in XOMA Royalty Corporation $XOMA

Nano Cap New Millennium Growth Fund L P bought a new position in shares of XOMA Royalty Corporation (NASDAQ:XOMA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,000 shares of the biotechnology company’s stock, valued at approximately $399,000. Nano Cap New Millennium Growth Fund L P owned about 0.12% of XOMA Royalty at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Diversified Management Inc. acquired a new position in XOMA Royalty during the 4th quarter valued at approximately $266,000. State of Alaska Department of Revenue acquired a new position in XOMA Royalty during the 4th quarter valued at approximately $27,000. SG Americas Securities LLC acquired a new position in XOMA Royalty during the 4th quarter valued at approximately $169,000. Woodline Partners LP increased its stake in XOMA Royalty by 16.5% during the 3rd quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in XOMA Royalty during the 3rd quarter valued at approximately $292,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. TD Cowen raised XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Thursday, April 30th. Finally, Weiss Ratings cut XOMA Royalty from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $53.75.

XOMA Royalty Stock Down 0.4%

XOMA stock opened at $41.82 on Friday. The firm’s fifty day simple moving average is $36.10 and its 200-day simple moving average is $30.80. The company has a market capitalization of $524.46 million, a P/E ratio of 26.64 and a beta of 0.90. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. XOMA Royalty Corporation has a 12 month low of $22.29 and a 12 month high of $42.81.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). The business had revenue of $12.32 million during the quarter, compared to analysts’ expectations of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. As a group, equities research analysts forecast that XOMA Royalty Corporation will post 0.94 earnings per share for the current year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.